MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
March 23, 2026 11:00 AM EDTBelieves the Boards Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign
Commends New Leaderships Commitment to Shareholder Alignment Through Zero CEO Compensation
Expects Aurinia to Enter New Chapter of Disciplined Capital Allocation and Value Creation
CAYMAN ISLANDS--(BUSINESS WIRE)-- MKT Capital Ltd. (together with its affiliates, MKT Capital or we), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today issued the following statement in response to the Companys announcement... More
